Efficacy of alendronate for the treatment of ankylosing spondylitis: a protocol for systematic review and meta-analysis

Yu-hua Tang  
First Affiliated Hospital of Jiamusi University

Yu-zhi Li  
First Affiliated Hospital of Jiamusi University

Zhao-chen Tang  
Jiamusi University

Quan-wei Jiang  
Benxi Central Hospital of China Medical University

Yu Zhao (✉ taoyu200101@outlook.com)  
Huludao Central Hospital

Protocol

Keywords: Ankylosing spondylitis, alendronate, efficacy, safety

Posted Date: May 14th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-27663/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License

Version of Record: A version of this preprint was published at Medicine on July 24th, 2020. See the published version at https://doi.org/10.1097/MD.00000000000021089.
Abstract

Background Ankylosing spondylitis (AS) is a very tricky orthopedic disorder. If such condition can not be managed fairly well, it may significantly affect quality of life and even leads to disability among such population. A variety of studies have reported that alendronate is utilized for the treatment of AS. However, their results are still contrary, and no systematic review has addressed on this topic. Thus, this study will systematically assess the efficacy and safety of alendronate for the treatment of patients with AS.

Methods A comprehensive literature search will be performed from the below electronic databases from their commencement to the January 31, 2020 without language and publication status limitations: PUBMED, EMBASE, Cochrane Library, Web of Science, Allied and Complementary Medicine Database, WANGFANG, and China National Knowledge Infrastructure. Only randomized controlled trials (RCTs) focusing on the alendronate for the treatment of patients with AS will be considered for inclusion in this study. Two authors will independently select all identified records, extract essential data from all included studies, and appraise study quality for each eligible trial using Cochrane risk of bias. If any differences occur, another experienced author will be invited to solve them by discussion and a consensus decision will be made. We will implement RevMan 5.3 software to analyze the extracted data.

Results This study will summarize high quality RCTs to assess the efficacy and safety of alendronate for the treatment of patients with AS through primary outcome of bone densitometry; and secondary outcomes of pain intensity, quality of life, disease activity, functional status, and adverse events.

Conclusions This study will provide evidence to help determine whether alendronate is an effective and safe management for patient with AS or not.

Background

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease [1-3]. It is characterized by inflammation of spine and the sacroiliac joints [4-6], which causes structural and functional impairments of those joints and results in poor quality of life [7-9]. It is estimated that about 0.1% to 1.8% people affect this disorder and onset of symptoms commonly manifest in males between 15 and 25 years old [10-11]. To date, its etiology remains not fully elucidated [12-13].

Currently, very few medications can benefit patients with AS [14-16]. Recent studies reported to use alendronate for the treatment of patients with AS [17-23]. As far as we know, no previous systematic review has focused on the efficacy and safety of alendronate for treating AS. With the recent publication
of high quality studies on this subject [17-23], this study aims to systematically explore the efficacy and safety of alendronate for the treatment of patients with AS.

Methods And Analysis

Study registration

We have registered this study on INPLASY202040153. It is developed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement guidelines [24].

Eligibility criteria for study selection

Study types

This study will only include randomized controlled trials (RCTs) of alendronate for the treatment of patients with AS. Besides RCTs, we will exclude any other studies, such as non-clinical trials, non-RCTs, and quasi-RCTs.

Intervention types

The experimental intervention are any forms of alendronate.

The control intervention could be any treatments, such as placebo, other medications, and alternative therapies. However, we will exclude studies using any types of alendronate, including its combination with other managements as their comparators.

Patient types

Any adult participants (more than 18 years old) with a definite diagnosis of AS will be included in spite of their race, gender, educational background, and duration of AS.

Outcome measurements

Primary outcome

Bone densitometry (as reported in the trials by any instruments or tools).
Secondary outcomes

Pain intensity (as reported in the trial by any pain scales);

Quality of life (as reported in the trial by any tools, such as Ankylosing Spondylitis Quality of Life questionnaire);

Disease activity (as reported in the trial by any indexes, such as Bath Ankylosing Spondylitis Disease Activity Index);

Functional status (as reported in the trial by any scores, such as Bath Ankylosing Spondylitis Functional Index); and

Adverse events.

Search strategy

Electronic databases search

Two authors will carry out a comprehensive literature search from the below electronic databases: PUBMED, EMBASE, Cochrane Library, Web of Science, Allied and Complementary Medicine Database, WANGFANG, and China National Knowledge Infrastructure. All these electronic databases will be searched from their commencement to the January 31, 2020 without language and publication status limitations. Any potential randomized controlled trials (RCTs) that explored the efficacy and safety of alendronate for the treatment of patients with AS will be included. An example of detailed search strategy for PUBMED is presented (table 1). We will modify similar search strategies for other electronic databases.

Other literature sources search

We will search other literature resources, such as Google Scholar, websites of clinical trial registry, dissertations, and reference lists of included trials.

Literature selection

Records from all literature source searches will be imported into EndNote X9 to remove all duplicated studies. Two authors will firstly identify records by scanning titles and abstracts, and unrelated studies
will be eliminated. Then, full-text of remaining studies will be read cautiously based on the predefined eligibility criteria. Any divergences will be figured out with the help of a third author. The process of study selection will be exerted in a flow diagram (Figure 1).

Data collection and management

Two authors will independently extract data from each included trial in accordance with the predefined data collection form. Any uncertainties will be resolved by another author and a consensus will be reached finally. The collected information is as follows:

Study details: title, first author, publication date, location, et al.

Study methods: randomization specifics, blinding, allocation, follow-up information, et al.

Patient characteristics: age, sex, sample size, duration and severity of AS, et al.

Intervention and control details: treatment duration, dosage, frequency, et al.

Outcomes: outcome measurements reported in the trial, adverse events, et al.

Others: funding information, conflict of interest, et al.

Dealing with unclear or missing data

Any unclear or insufficient data will be obtained from original authors with email or phone. If it is not achievable, we will perform data analysis based on the available data, and will discuss its impacts on study findings.

Risk of bias assessment

Study quality of each included trial will be evaluated by two independent authors using Cochrane risk of bias tool, which examines 7 domains. We will rate each source of bias as low, unclear or high. Any different views will be worked out with the help of another author through discussion.

Treatment effect measurement

In this study, we will use mean difference or standardized mean difference and 95% confidence intervals (CIs) to evaluate the treatment effect for continuous data, and risk ratio and 95% CIs to appraise the
treatment effect for dichotomous data.

Data analysis

RevMan 5.3 software will be employed for all data analysis and meta-analysis if it is possible. $I^2$ test will be used for heterogeneity identification. $I^2 \leq 50\%$ suggests reasonable heterogeneity, and a fixed-effect model will be exerted. Otherwise, $I^2 > 50\%$ means substantial heterogeneity, and a random-effect model will be employed. If ample data is extracted from sufficient trials with low heterogeneity, we will carry out meta-analysis to explain the results. On the other hand, we will perform subgroup analysis and sensitivity analysis to test possible sources of significant heterogeneity. If meta-analysis is deemed not to be conducted, we will elaborate study results using a narrative description.

Subgroup analysis

Subgroup analysis will be developed to investigate the possible sources of significant heterogeneity according to the characteristics of study, types of intervention and controls, and different outcome measurements.

Sensitivity analysis

A sensitivity analysis will be carried out to test the robustness and stability of pooled results by taking away low quality trials or trials reporting data missing.

Reporting bias

If it is possible to include at least 10 trials on one outcome, we will examine the possible reporting bias using funnel plot and Egger's regression test [25-26].

Dissemination

This study will be disseminated at a peer-reviewed journal or will be presented a scientific conference.

Discussion
Alendronate is used to treat several osteoporosis diseases, including AS. For patients with AS, alendronate has been investigated in several clinical trials. However, its efficacy and safety on AS is still inconsistent. Hence, this study will assess the efficacy and safety of alendronate in patients with AS. This study may provide helpful evidence to judge whether alendronate is effective and safety in patients with AS.

This study still has several limitations. First, significant heterogeneity may exist, which may affect the accuracy of the findings. Second, AS severity and baseline characteristics of the patients may be vary among trials, this may impede its generation to all AS patients. Third, the number of eligible trials and patient samples may be relatively small, which may weaken the power of the present study.

**Abbreviations**

AS, ankylosing spondylitis; RCTs, randomized controlled trials; CIs, confidence intervals.

**Declarations**

**Ethics approval and consent to participate**: Not applicable

**Consent for publication**: Not applicable

**Availability of data and material**: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current protocol

**Competing interests**: None.

**Funding**: This study was supported by Scientific Research Project of Heilongjiang Health and Family Planning Commission (2017-387). The supporters had no role in this study.

**Authors’ contributions**: YHT and YZ conceived the study. YZL and ZCT contributed with the clinical background and expertise. YZL, ZCT and QWJ contributed with the analytical plan and the bias
assessment approach. YHT and YZL performed the literature search plan. ZCT, QWJ and YZ drafted the protocol. All authors revised the protocol and approved the final version. YZ supervised the study.

Acknowledgements: Not applicable.

Authors' information: Yu-hua Tang, huayut@outlook.com
Yu-zhi Li, xuancang8173@126.com
Zhao-chen Tang, baoliaoyue794393@126.com
Quan-wei Jiang, neanenmjqqg@outlook.com
Yu Zhao, Yuzhao2001@outlook.com

References


Tables

Table 1 Search strategy of PUBMED
<table>
<thead>
<tr>
<th>Number</th>
<th>Search terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ankylosing spondylitis</td>
</tr>
<tr>
<td>2</td>
<td>Bechterew’s disease</td>
</tr>
<tr>
<td>3</td>
<td>uveitis</td>
</tr>
<tr>
<td>4</td>
<td>joint stiffness</td>
</tr>
<tr>
<td>5</td>
<td>inflammation</td>
</tr>
<tr>
<td>6</td>
<td>spine</td>
</tr>
<tr>
<td>7</td>
<td>arthritis</td>
</tr>
<tr>
<td>8</td>
<td>Or 1-7</td>
</tr>
<tr>
<td>9</td>
<td>alendronate</td>
</tr>
<tr>
<td>10</td>
<td>Binosto</td>
</tr>
<tr>
<td>11</td>
<td>Fosamax Plus D</td>
</tr>
<tr>
<td>12</td>
<td>Fosamax</td>
</tr>
<tr>
<td>13</td>
<td>Or 9-12</td>
</tr>
<tr>
<td>14</td>
<td>randomized controlled trials</td>
</tr>
<tr>
<td>15</td>
<td>random</td>
</tr>
<tr>
<td>16</td>
<td>control</td>
</tr>
<tr>
<td>17</td>
<td>allocation</td>
</tr>
<tr>
<td>18</td>
<td>placebo</td>
</tr>
<tr>
<td>19</td>
<td>clinical trial</td>
</tr>
<tr>
<td>20</td>
<td>controlled study</td>
</tr>
<tr>
<td>21</td>
<td>Or 14-20</td>
</tr>
<tr>
<td>22</td>
<td>8 and 13 and 21</td>
</tr>
</tbody>
</table>

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- **PRISMAPchecklist.doc**